- Home
- BRTX vs INDP Comparison
BRTX vs INDP Comparison
Compare BRTX & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- INDP
- Stock Information
- Founded
- BRTX 1997
- INDP 2000
- Country
- BRTX United States
- INDP United States
- Employees
- BRTX N/A
- INDP N/A
- Industry
- BRTX Managed Health Care
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- BRTX Health Care
- INDP Health Care
- Exchange
- BRTX Nasdaq
- INDP Nasdaq
- Market Cap
- BRTX 11.3M
- INDP 12.1M
- IPO Year
- BRTX N/A
- INDP N/A
- Fundamental
- Price
- BRTX $1.46
- INDP $1.11
- Analyst Decision
- BRTX Strong Buy
- INDP Strong Buy
- Analyst Count
- BRTX 1
- INDP 2
- Target Price
- BRTX $18.00
- INDP $8.50
- AVG Volume (30 Days)
- BRTX 34.6K
- INDP 304.4K
- Earning Date
- BRTX 11-12-2024
- INDP 11-12-2024
- Dividend Yield
- BRTX N/A
- INDP N/A
- EPS Growth
- BRTX N/A
- INDP N/A
- EPS
- BRTX N/A
- INDP N/A
- Revenue
- BRTX $377,000.00
- INDP N/A
- Revenue This Year
- BRTX $598.90
- INDP N/A
- Revenue Next Year
- BRTX $162.81
- INDP N/A
- P/E Ratio
- BRTX N/A
- INDP N/A
- Revenue Growth
- BRTX 189.55
- INDP N/A
- 52 Week Low
- BRTX $1.03
- INDP $1.03
- 52 Week High
- BRTX $3.67
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- BRTX 39.02
- INDP 41.16
- Support Level
- BRTX $1.44
- INDP $1.13
- Resistance Level
- BRTX $1.78
- INDP $1.31
- Average True Range (ATR)
- BRTX 0.16
- INDP 0.10
- MACD
- BRTX -0.01
- INDP -0.01
- Stochastic Oscillator
- BRTX 24.93
- INDP 8.57
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.